Salome Christen1, Janine Vetsch1, Luzius Mader1, Silvia Dehler2, Dimitri Korol2, Claudia Kuehni3, Corina S Rueegg1, Gisela Michel4,5. 1. Department of Health Sciences & Health Policy, University of Lucerne, Frohburgstrasse 3, 6002, Lucerne, Switzerland. 2. Cancer Registry Zurich and Zug, Institute of Surgical Pathology, University Hospital Zurich and Epidemiology, Biostatistics and Prevention Institute, University Zurich, Vogelsangstrasse 10, 8091, Zurich, Switzerland. 3. Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012, Bern, Switzerland. 4. Department of Health Sciences & Health Policy, University of Lucerne, Frohburgstrasse 3, 6002, Lucerne, Switzerland. gisela.michel@unilu.ch. 5. Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012, Bern, Switzerland. gisela.michel@unilu.ch.
Abstract
PURPOSE: As survival rates of adolescent and young adult (AYA) cancer patients increase, a growing number of AYA cancer survivors need follow-up care. However, there is little research on their preferences for follow-up care. We aimed to (1) describe AYA cancer survivors' preferences for the organization and content of follow-up care, (2) describe their preferences for different models of follow-up, and (3) investigate clinical and sociodemographic characteristics associated with preferences for the different models. METHODS: AYA cancer survivors (diagnosed with cancer at age 16-25 years; ≥5 years after diagnosis) were identified through the Cancer Registry Zurich and Zug. Survivors completed a questionnaire on follow-up attendance, preferences for organizational aspects of follow-up care (what is important during follow-up, what should be included during appointments, what specialists should be involved, location), models of follow-up (telephone/questionnaire, general practitioner (GP), pediatric oncologist, medical oncologist, multidisciplinary team), and sociodemographic characteristics. Information on tumor and treatment was available through the Cancer Registry Zurich and Zug. RESULTS: Of 389 contacted survivors, 160 (41.1 %) participated and 92 (57.5 %) reported still attending follow-up. Medical aspects of follow-up care were more important than general aspects (p < 0.001). Among different organizational models, follow-up by a medical oncologist was rated higher than all other models (p = 0.002). Non-attenders of follow-up rated GP-led follow-up significantly higher than attenders (p = 0.001). CONCLUSION: Swiss AYA cancer survivors valued medical content of follow-up and showed a preference for medical oncologist-led follow-up. Implementation of different models of follow-up care might improve accessibility and attendance among AYA cancer survivors.
PURPOSE: As survival rates of adolescent and young adult (AYA) cancerpatients increase, a growing number of AYA cancer survivors need follow-up care. However, there is little research on their preferences for follow-up care. We aimed to (1) describe AYA cancer survivors' preferences for the organization and content of follow-up care, (2) describe their preferences for different models of follow-up, and (3) investigate clinical and sociodemographic characteristics associated with preferences for the different models. METHODS: AYA cancer survivors (diagnosed with cancer at age 16-25 years; ≥5 years after diagnosis) were identified through the Cancer Registry Zurich and Zug. Survivors completed a questionnaire on follow-up attendance, preferences for organizational aspects of follow-up care (what is important during follow-up, what should be included during appointments, what specialists should be involved, location), models of follow-up (telephone/questionnaire, general practitioner (GP), pediatric oncologist, medical oncologist, multidisciplinary team), and sociodemographic characteristics. Information on tumor and treatment was available through the Cancer Registry Zurich and Zug. RESULTS: Of 389 contacted survivors, 160 (41.1 %) participated and 92 (57.5 %) reported still attending follow-up. Medical aspects of follow-up care were more important than general aspects (p < 0.001). Among different organizational models, follow-up by a medical oncologist was rated higher than all other models (p = 0.002). Non-attenders of follow-up rated GP-led follow-up significantly higher than attenders (p = 0.001). CONCLUSION: Swiss AYA cancer survivors valued medical content of follow-up and showed a preference for medical oncologist-led follow-up. Implementation of different models of follow-up care might improve accessibility and attendance among AYA cancer survivors.
Entities:
Keywords:
AYA; Adolescent and young adult cancer survivors; Long-term follow-up; Models of care; Preferences
Authors: Claudia E Kuehni; Corina S Rueegg; Gisela Michel; Cornelia E Rebholz; Marie-Pierre F Strippoli; Felix K Niggli; Matthias Egger; Nicolas X von der Weid Journal: Int J Epidemiol Date: 2011-10-27 Impact factor: 7.196
Authors: Kate Absolom; Diana Greenfield; Richard Ross; Beverly Horne; Helena Davies; Adam Glaser; Adrian Simpson; Heather Waite; Christine Eiser Journal: Eur J Cancer Date: 2006-06-08 Impact factor: 9.162
Authors: David G Poplack; Michael Fordis; Wendy Landier; Smita Bhatia; Melissa M Hudson; Marc E Horowitz Journal: Nat Rev Clin Oncol Date: 2014-10-28 Impact factor: 66.675
Authors: Gemma Gatta; Giulia Zigon; Riccardo Capocaccia; Jan Willem Coebergh; Emmanuel Desandes; Peter Kaatsch; Guido Pastore; Rafael Peris-Bonet; Charles A Stiller Journal: Eur J Cancer Date: 2009-02-21 Impact factor: 9.162
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079
Authors: Linda C Harlan; Charles F Lynch; Theresa H M Keegan; Ann S Hamilton; Xiao-Cheng Wu; Ikuko Kato; Michele M West; Rosemary D Cress; Stephen M Schwartz; Ashley W Smith; Dennis Deapen; Sonja M Stringer; Arnold L Potosky Journal: J Cancer Surviv Date: 2011-01-28 Impact factor: 4.442
Authors: Gisela Michel; Renée L Mulder; Helena J H van der Pal; Roderick Skinner; Edit Bárdi; Morven C Brown; Janine Vetsch; Eva Frey; Rachael Windsor; Leontien C M Kremer; Gill Levitt Journal: J Cancer Surviv Date: 2019-08-08 Impact factor: 4.442
Authors: Samantha T Pannier; Echo L Warner; Brynn Fowler; Douglas Fair; Sara K Salmon; Anne C Kirchhoff Journal: J Cancer Educ Date: 2019-04 Impact factor: 2.037
Authors: Claire Snyder; Youngjee Choi; Katherine C Smith; Renee F Wilson; Christina T Yuan; Paul C Nathan; Allen Zhang; Karen A Robinson Journal: JNCI Cancer Spectr Date: 2022-03-02
Authors: Thijs Wieldraaijer; Marike de Meij; Sophie Zwaard; Henk van Weert; Jan Wind Journal: Eur J Cancer Care (Engl) Date: 2019-08-30 Impact factor: 2.520
Authors: T Wieldraaijer; L A M Duineveld; S C Donkervoort; W B Busschers; H C P M van Weert; J Wind Journal: Scand J Prim Health Care Date: 2018-01-17 Impact factor: 2.581
Authors: Salome Christen; Katharina Roser; Renée L Mulder; Anica Ilic; Hanne C Lie; Jacqueline J Loonen; Anneli V Mellblom; Leontien C M Kremer; Melissa M Hudson; Louis S Constine; Roderick Skinner; Katrin Scheinemann; Jordan Gilleland Marchak; Gisela Michel Journal: J Cancer Surviv Date: 2020-08-25 Impact factor: 4.442
Authors: Dalia Kagramanov; Rinku Sutradhar; Cindy Lau; Zhan Yao; Jason D Pole; Nancy N Baxter; Sumit Gupta; Paul C Nathan Journal: Cancer Med Date: 2021-06-15 Impact factor: 4.452